General
Preferred name
METHYLDOPA
Synonyms
L-alpha-Methyl DOPA ()
L-(-)- α-Methyldopa ()
L-(-)-¦Á-Methyldopa (hydrochloride) ()
Methyldopa hydrochloride ()
L-(-)-α-Methyldopa ()
MK-351 ()
L-(-)-??-Methyldopa (hydrochloride) ()
Methyldopa (L,-) ()
METHYLDOPA ANHYDROUS ()
Methyldopa Sesquihydrate ()
MK-351 hydrochloride ()
L-α-Methyl DOPA Hydrate ()
L-methyldopa ()
Methyldopa hydrate ()
L-(-)-¦Á-Methyldopa hydrate ()
Methyldopa hydrate, MK-351 hydrate ()
L-(-)-¦Á-Methyldopa ()
L-α-methyldopa ()
Medopren ()
Metildopa ()
Methyldopa component of aldoril ()
Dopamet ()
Alpha-Methyldopa ()
Metalpha 250 ()
Metalpha 500 ()
(-)-.alpha.-methyldopa ()
Methyldopa, anhydrous ()
Methyldopa (levorotatory) ()
Aldomet ()
Anhydrous methyldopa ()
.alpha.-methyl-l-dopa ()
BAYER-1440L ()
NSC-169916 ()
Dopegyt ()
Lederdopa ()
Medomet ()
L-.alpha.-methyldopa ()
NSC-760080 ()
J9.247I ()
(s)-(-)-.alpha.-methyldopa ()
Presinol ()
L-(-)-?-Methyldopa ()
P&D ID
PD001858
CAS
41372-08-1
133161-54-3
884-39-9
555-30-6
Tags
available
drug
Approved by
FDA
First approval
1962
Drug indication
Hypertension
preeclampsia
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
L-α-methyldopa is metabolised to α-methylnorepinephrine in the brain, the metabolite being a selective agonist of α2 adrenoceptors. Clinical L-α-methyldopa use has largely been replaced by safer alternatives.
(GtoPdb)
DESCRIPTION
Methyldopa (L-(-)-¦Á-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for ¦Á2-adrenergic receptors). Methyldopa is a proagent and is metabolized (¦Á-Methylepinephrine) in the central nervous system[1][2].
PRICE
29
DESCRIPTION
Methyldopa (MK-351), an alpha-adrenergic agonist (selective for ??2-adrenergic receptors) psychoactive medicine, is served as an antihypertensive or sympatholytic.
PRICE
29
DESCRIPTION
Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect ??2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.
DESCRIPTION
Methyldopa is a centrally-acting alpha-2 adrenergic agonist. It is used to manage hypertension alone or in combination with hydrochlorothiazide, and to treat hypertensive crises.
(Enamine Bioactive Compounds)
DESCRIPTION
L-aromatic amino acid decarboxylase inhibitor; antihypertensive
(LOPAC library)
DESCRIPTION
Aromatic L-amino acid decarboxylase inhibitor
(Tocriscreen Total)
DESCRIPTION
Methyldopa (Aldomet) is a DOPA decarboxylase competitive inhibitor with an ED50 of 21.8 mg/kg.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Methyldopa (MK-351), an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive medicine, is served as an antihypertensive or sympatholytic.
(TargetMol Bioactive Compound Library)
DESCRIPTION
MK-351 hydrochloride is an alpha-adrenergic agonist selective for α2-adrenergic receptors. It is a psychoactive drug used as a sympatholytic or antihypertensive. It plays a role in treating hypertension and gestational hypertension. It has a dual mechanism of action. It is a competitive inhibitor of the enzyme DOPA decarboxylase, which converts L-DOPA into dopamine. It is converted to α-methylnorepinephrine by dopamine beta-hydroxylase.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
L-α-Methyl DOPA Hydrate is an alpha-adrenergic agonist used as a sympatholytic or antihypertensive.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
34
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
100
Molecular Weight
211.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
0.44
TPSA
103.78
Fraction CSP3
0.3
Chiral centers
1.0
Largest ring
6.0
QED
0.54
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
Aromatic amino acid decarboxylase
Target
Adrenergic Receptor
Adrenergic receptor alpha-2
Dopa decarboxylase
ADRA2A, ADRA2B, ADRA2C, DDC
5-HT Receptor,Adrenergic Receptor,Decarboxylase,Dopamine Receptor
Endogenous Metabolite
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Metabolic Enzyme/Protease
MOA
Dopa decarboxylase inhibitor
Adrenergic Receptor agonist
Indication
hypertension
Therapeutic Class
Antihypertensive Agents
Solubility
10 mM in DMSO
Soluble in DMSO
Source data

